Cargando…
Absent in melanoma 2 enhances anti‐tumour effects of CAIX promotor controlled conditionally replicative adenovirus in renal cancer
Conditionally replicative adenoviruses (CRAds) were promising approach for solid tumour treatment, but its oncolytic efficiency and toxicity are still not satisfactory for further clinical application. Here, we developed the CAIX promotor (CAIX(promotor))‐controlled CRAd armed with a tumour suppress...
Autores principales: | Chai, Dafei, Qiu, Dong, Zhang, Zichun, Yuchen Shi, Shang, Wang, Gang, Fang, Lin, Li, Huizhong, Li, Hailong, Tian, Hui, Zheng, Junnian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7521288/ https://www.ncbi.nlm.nih.gov/pubmed/32725966 http://dx.doi.org/10.1111/jcmm.15697 |
Ejemplares similares
-
Absent in melanoma 2-mediating M1 macrophages facilitate tumor rejection in renal carcinoma
por: Chai, Dafei, et al.
Publicado: (2021) -
Dual-targeting vaccine of FGL1/CAIX exhibits potent anti-tumor activity by activating DC-mediated multi-functional CD8 T cell immunity
por: Chai, Dafei, et al.
Publicado: (2021) -
Co‐immunization with L‐Myc enhances CD8(+) or CD103(+) DCs mediated tumor‐specific multi‐functional CD8(+) T cell responses
por: Chai, Dafei, et al.
Publicado: (2021) -
IFI35 Promotes Renal Cancer Progression by Inhibiting pSTAT1/pSTAT6-Dependent Autophagy
por: Chai, Dafei, et al.
Publicado: (2022) -
Oncolytic adenovirus-mediated expression of decorin facilitates CAIX-targeting CAR-T therapy against renal cell carcinoma
por: Zhang, Chen, et al.
Publicado: (2021)